Network Open, point to digital shifts in cardiovascular care amid the ongoing COVID-19 pandemic. We were encouraged to learn that access to cardiovascular care was maintained for high-risk and underserved communities during the pandemic, said Joseph Ebinger, MD, director of Clinical Analytics in the Smidt Heart Institute and senior author of the study. This same study, however, identified some differences in care that we need to delve into further to better understand.
The researchers examined data collected from 87,182 pre-COVID in-person visits, 74,498 COVID-era in-person visits, 4,720 COVID-era telehealth video visits and 10,381 COVID-era telephone visits.
Across all categories, patients accessing COVID-era remote visits were more likely to be from racial or ethnic minority groups, have private insurance and have cardiovascular conditions such as hypertension, coronary artery disease, atrial fibrillation and heart failure.
Heart in a Box Technology Expands Heart Transplant Window
Smidt Heart Institute uses Transmedics Organ Care System (OCS) to increase the geographic area of service to enable more organ transplants
The Transmedics Organ Care System (OCS) Heart, or “Heart in a Box,” enables transplant surgeons to travel to much farther destinations to procure transplant hearts by acting as a miniature intensive care unit that keeps the heart alive.
April 5, 2021 Smidt Heart Institute transplant surgeons Dominic Emerson, M.D., and Pedro Catarino, M.D. know how to be spontaneous. At any given moment, they can get the call that a donor heart or lungs are available, requiring them to quickly board a private aircraft to procure the vital organs. But until recently, those flights were quick jaunts lasting no more than four hours the time a donor heart can survive on ice. Now that is all changing, thanks to a medical device called the Transmedics Organ Care System (OCS) Heart, or “Heart in a Box
Single-dose of COVID-19 Vaccine Stimulates Immunity in COVID-19 Survivors medindia.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medindia.net Daily Mail and Mail on Sunday newspapers.
By City News Service
Apr 1, 2021
LOS ANGELES (CNS) - A single dose of the Pfizer-BioNTech vaccine for people who have already had COVID-19 generates an immunologic response similar to that in people who receive the two-dose recommended sequence, according to a study released today by researchers at Cedars-Sinai.
The study suggests that the second dose may not be needed for people who have successfully recovered from a prior coronavirus infection, according to Dr. Susan Cheng, an associate professor of cardiology and director of Public Health Research at the Smidt Heart Institute at Cedars-Sinai.
“Our findings extend those from smaller studies reported elsewhere and support a potential strategy of providing a single dose of vaccine to persons with a confirmed prior history of coronavirus infection, along with two doses for people not previously infected, Cheng said. “This approach could maximize the reach of a limited vaccine supply, allowing potentially millions more people
Credit: Photo by Cedars-Sinai
JAMA (the
Journal of the American Medical Association) confirms that neither vitamin D nor the omega-3 fatty acids found in fish oil prevent the development of atrial fibrillation (AF), a potentially serious heart rhythm disturbance. The newly published research follows a presentation made by Christine Albert, MD, MPH, at the American Heart Association Scientific Sessions last year.
In their
JAMA analysis, Albert and her research team also examined whether vitamin D or omega-3 fatty acids might have an impact on paroxysmal versus persistent atrial fibrillation and whether there might be certain subgroups of patients who would be more likely to benefit or be harmed by the supplements. Overall, the results were mostly consistent across types of AF and groups of patients.